CRP and COVID-19: Finally, another study has demonstrated that use of tocilizumab in COVID-19 patients (n = 79) was correlated with decreased need of mechanical ventilation and blood total leukocytes and neutrophils count and serum CRP levels even with several dosages such as < 400 mg/die, 400–800 mg/die and > 800 mg/die and with different timing of starting treatment such as 1–7 days post symptoms onset, 8–15 days, or more than 16 days, compared to COVID-19 treated with standard care.